SCHEMBL3013196

SCHEMBL3013196

O=S(=O)(c1c(F)cccc1F)N1CCN(c2nc(Cc3cc(Cl)cc(Cl)c3)cs2)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PKM P14618 12/20 0.46
PKLR P30613 7/20 0.46
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KMT2A Q03164 3/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 2/20 0.40
LMNA P02545 2/20 0.40
USP2 O75604 1/20 0.40
RECQL P46063 1/20 0.40
HSD17B10 Q99714 1/20 0.40
AR P10275 1/20 0.40
MAPK1 P28482 1/20 0.38
RAB9A P51151 1/20 0.38
THRB P10828 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012169 0.95 PKM (0.43) PKMPKLRALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3020835 0.91 PKM (0.45) PKMPKLRALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3011177 0.91 PKM (0.47) PKMPKLRALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3010024 0.90 PKM (0.48) PKMPKLRALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3003766 0.89 PKM (0.45) PKMPKLRALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3004781 0.89 PKM (0.45) PKMPKLRALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3019651 0.89 PKM (0.47) PKMPKLRALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3011284 0.89 SMN1; SMN2 (0.40) PKMALDH1A1SMN1; SMN2L3MBTL1KMT2A
SCHEMBL3011274 0.88 PKM (0.46) PKMPKLRALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3015815 0.88 PKM (0.50) PKMPKLRALDH1A1SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA PKM 1047/4885PKLR 2799/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.